Literature DB >> 27215204

Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?

Oliver FitzGerald1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27215204     DOI： 10.1038/nrrheum.2016.84

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment.

Authors:  A W R van Kuijk; P Reinders-Blankert; T J M Smeets; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2006-05-25       Impact factor: 19.103

2.  The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.

Authors:  Philip J Mease; Alice B Gottlieb; Alberto Berman; Edit Drescher; Jun Xing; Robert Wong; Subhashis Banerjee
Journal:  Arthritis Rheumatol       Date:  2016-09       Impact factor: 10.995

3.  Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.

Authors:  Karen Minde Fagerli; Elisabeth Lie; Désirée van der Heijde; Marte Schrumpf Heiberg; Synøve Kalstad; Erik Rødevand; Knut Mikkelsen; Ase Stavland Lexberg; Tore K Kvien
Journal:  Ann Rheum Dis       Date:  2013-04-05       Impact factor: 19.103

4.  High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires.

Authors:  Muhammad Haroon; Brian Kirby; Oliver FitzGerald
Journal:  Ann Rheum Dis       Date:  2012-06-23       Impact factor: 19.103

5.  Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis: correlations with clinical and laboratory parameters.

Authors:  A Spadaro; E Taccari; V Riccieri; F Sensi; A Sili Scavalli; A Zoppini
Journal:  Clin Exp Rheumatol       Date:  1996 Jul-Aug       Impact factor: 4.473

6.  Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.

Authors:  Laura C Coates; Anna R Moverley; Lucy McParland; Sarah Brown; Nuria Navarro-Coy; John L O'Dwyer; David M Meads; Paul Emery; Philip G Conaghan; Philip S Helliwell
Journal:  Lancet       Date:  2015-10-01       Impact factor: 79.321

7.  Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.

Authors:  G Partsch; G Steiner; B F Leeb; A Dunky; H Bröll; J S Smolen
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

8.  Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis?

Authors:  G-M Alenius; C Eriksson; S Rantapää Dahlqvist
Journal:  Clin Exp Rheumatol       Date:  2009 Jan-Feb       Impact factor: 4.473

9.  Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.

Authors:  Bente Glintborg; Mikkel Ostergaard; Niels Steen Krogh; Martin Dehn Andersen; Ulrik Tarp; Anne Gitte Loft; Hanne M Lindegaard; Mette Holland-Fischer; Henrik Nordin; Dorte Vendelbo Jensen; Christian Holkmann Olsen; Merete Lund Hetland
Journal:  Arthritis Rheum       Date:  2013-05

10.  A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience.

Authors:  D Kane; L Stafford; B Bresnihan; O FitzGerald
Journal:  Rheumatology (Oxford)       Date:  2003-10-01       Impact factor: 7.580
  10 in total
  1 in total

1.  The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report.

Authors:  Patrice E Poubelle; Nathalie Pagé; Marie-Pier Longchamps; Natalia Sampaio Moura; David B Beck; Ivona Aksentijevich; Philippe A Tessier; Martin Pelletier
Journal:  Clin Transl Med       Date:  2019-06-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.